Christian S. Hinrichs, M.D.

Christian S. Hinrichs, M.D.
Special Volunteer

Dr. Hinrichs left CCR in January 2021.  He researched immunotherapy for HPV+ cancers, which include cervical, oropharyngeal, anal, vulvar, vaginal, and penile malignancies. Dr. Hinrichs discovered personalized cellular and gene therapies for HPV+ cancers. His laboratory studied why these treatments work in some patients and not in others and used what was learned to innovate more effective therapies.

Areas of Expertise

1) immunotherapy, 2) cell therapy, 3) human papillomavirus, 4) cervical cancer, 5) oropharyngeal cancer, 6) anal cancer

Contact Info

Christian S. Hinrichs, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 4B04
Bethesda, MD 20892
Ph: 240-760-6059
Fax: 240-541-4541
hinrichs@mail.nih.gov

Cellular Therapy for Cancer

Dr. Hinrichs conducted basic and clinical research to discover and develop novel T cell therapies for the treatment of patients with cancer. This work includes a clinical trial of human papillomavirus (HPV)-targeted tumor-infiltrating T cells for patients with HPV+ cancers, which has demonstrated that this treatment can mediate complete regression of cervical cancer in some patients. Dr. Hinrichs' laboratory also discovered genes for T cell receptors that target HPV, and his group tested new gene therapy treatments based on these receptors for patients with advanced HPV+ tumors.

NIH Scientific Focus Areas:
Biomedical Engineering and Biophysics, Cancer Biology, Clinical Research, Immunology, Virology
View Dr. Hinrichs' PubMed Summary.

Selected Recent Publications

  1. Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS.
    J Clin Oncol. 37(30): 2759-68, 2019. [ Journal Article ]
  2. Stevanović S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS.
    Clin Cancer Res. 25(5): 1486-93, 2019. [ Journal Article ]
  3. Hinrichs CS
    J Clin Invest. 128(4): 1261-63, 2018. [ Journal Article ]
  4. Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS.
    Science. 356(6334): 200-205, 2017. [ Journal Article ]
  5. Draper LM, Kwong ML, Gros A, Stevanovic S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS
    Clin Cancer Res. 21(19): 4431-9, 2015. [ Journal Article ]

Dr. Hinrichs received his B.A. and M.D. degrees from the combined 6-year program at the University of Missouri - Kansas City (UMKC). He trained in general surgery at UMKC and in surgical oncology at Roswell Park Cancer Institute. He then completed a surgical oncology and tumor immunology fellowship at the National Cancer Institute (NCI). Subsequently he trained in internal medicine at George Washington University and in medical oncology at the Medical Oncology Branch of the NCI. He was awarded tenure at NIH in 2020. Dr. Hinrichs conducts basic research and clinical research to develop T-cell therapies for HPV-associated cancers and other epithelial malignancies.

For Researchers

Plasmids

Christian Hinrichs Lab Plasmids - Our lab has deposited plasmids at Addgene for distribution to the research community. Addgene is a nonprofit plasmid repository dedicated to improving life science research.

Protocols

SOP-D-001 - 293GP Retroviral Production

SOP-D-002 - Retroviral Transduction of Human T Cells